NAS:IMCC (Israel)
Â
Business Description
IM Cannabis Corp
NAICS : 325412
SIC : 3741
Description
IM Cannabis Corp is a Canada-based international medical cannabis company. It offers government-licensed cannabis products, from generic to GMP-certified and pharmaceutical-grade, for both wholesale and retail clients. The majority of its revenues are generated from sales of medical cannabis products to customers in Israel and recreational cannabis in Canada. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.42 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -0.33 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.5 | |||||
| Beneish M-Score | -8.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.4 | |||||
| 3-Year EPS without NRI Growth Rate | -40.1 | |||||
| 3-Year FCF Growth Rate | -54.2 | |||||
| 3-Year Book Growth Rate | -35.8 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.95 | |||||
| 9-Day RSI | 20.1 | |||||
| 14-Day RSI | 23.15 | |||||
| 6-1 Month Momentum % | -59.37 | |||||
| 12-1 Month Momentum % | -89.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.39 | |||||
| Quick Ratio | 1.15 | |||||
| Cash Ratio | 0.05 | |||||
| Days Inventory | 132.71 | |||||
| Days Sales Outstanding | 68.66 | |||||
| Days Payable | 64.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -306.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 19.06 | |||||
| Operating Margin % | -55.24 | |||||
| Net Margin % | -184.38 | |||||
| ROE % | -100.81 | |||||
| ROA % | -68.84 | |||||
| ROIC % | -24.38 | |||||
| ROC (Joel Greenblatt) % | -56.07 | |||||
| ROCE % | -16.48 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.2 | |||||
| PB Ratio | 0.32 | |||||
| Price-to-Tangible-Book | 0.45 | |||||
| EV-to-EBIT | -0.66 | |||||
| EV-to-EBITDA | -0.88 | |||||
| EV-to-Forward-EBITDA | 15.54 | |||||
| EV-to-Revenue | 0.23 | |||||
| EV-to-Forward-Revenue | 0.38 | |||||
| EV-to-FCF | -2.72 | |||||
| Price-to-Net-Current-Asset-Value | 0.8 | |||||
| Earnings Yield (Greenblatt) % | -151.52 |